SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc. is considered overvalued due to a significant downgrade in its investment appeal, reflected by a Price to Book Value of 5.79, a negative Return on Equity of -97.73%, and negative EV to EBITDA and EV to EBIT ratios, despite a strong year-to-date stock performance of 64.42%.

As of June 20, 2025, SELLAS Life Sciences Group, Inc. shows a mildly bullish trend, supported by bullish weekly MACD and Bollinger Bands, despite a bearish monthly RSI indicating some underlying weakness.

As of March 2022, the management team of SELLAS Life Sciences Group, Inc. includes Ms. Jane Wasman (Independent Chairman), Dr. Angelos Stergiou (President and CEO), Dr. David Scheinberg (Director), and Independent Directors Mr. Robert Van Nostrand and Mr. John Varian. They are responsible for the company's strategic direction and operations.

SELLAS Life Sciences Group, Inc. is a biopharmaceutical company focused on developing targeted oncology therapeutics. As of March 2025, it has a market cap of $155.65 million and reported a net profit loss of $6 million.

As of Jun 18, SELLAS Life Sciences Group, Inc. has a market capitalization of 155.65 million, with net sales of 0.00 million and a net profit of -27.13 million over the latest four quarters. The company's shareholder's funds are 9.46 million, and total assets amount to 19.63 million.